Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia (PRECAVER)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Sao Paulo
-
Campinas, Sao Paulo, Brazil
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects eligible for the treatment of dyslipidemia with statins according the current guidelines NCEP ATPIII and IV Brazilian Guidelines of Dyslipidemia and Atherosclerosis Prevention.
- Patients with previous use of rosuvastatin for, at least, 15 days and, for no longer than12 months prior to the inclusion in the study.
Exclusion Criteria:
Pregnancy and childbearing
- History of severe hypersensitivity (including myopathy) to other HMG-CoA reductase inhibitors.
- Subjects with indication of use of cyclosporine and other associations of other lipid lowering drugs.
- Subjects with underlying diseases that may influence lipid levels (i.e. uncontrolled hypothyroidism defined as a Thyroid stimulating hormone (TSH) > 1.5 times upper level of normality (ULN) at Visit 1, AIDS, transplanted subjects, etc).
- History of drug and alcohol abuse.
- Current active liver disease or hepatic failure or elevations in ALT >3 times the ULN.
- Elevation of CPK > 3 times the ULN.
- Elevation in the seric creatinine > 2,0 mg / dL.
- History of malignancy in the last 5 years, except basal cell or squamous cell carcinoma of the skin (women with a history of Cervical dysplasia must be included, unless they have t3 clear consecutive Papanicolaou (Pap) smears , before the entry in the study).
- Any other known clinical condition that, in the opinion of the investigator, may compromise the subject's safety.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
1
Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
|
|
Group 2
Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated.
The positive impact of the information upon treatment will be statistically evaluated.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Assess the LDL-C reduction in the group exposed to the educational program compared to the group with routine orientation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Assess cardiovascular risk through Framingham's score, · · Identify personal characteristics of the study population regarding their health, compile demographic characteristics regarding education, economic and cultural status.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jose Eduardo Neves, MD, AstraZeneca Brazil Ltda
- Principal Investigator: Francisco Jose Saraiva, MD, PUC-Campinas
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NIS-CBR-CRE-2007/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.